Azarga receives positive CHMP opinion
Azarga (brinzolamide 1%/timolol 0.5% ophthalmic suspension; Alcon Laboratories) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), which recommends Azarga be granted marketing authorization from the European Medicines Agency (EMEA).
Azarga (brinzolamide 1%/timolol 0.5% ophthalmic suspension; Alcon Laboratories) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), which recommends Azarga be granted marketing authorization from the European Medicines Agency (EMEA). The drug has been found, during a head-to-head study, to be equally effective in lowering intraocular pressure (IOP) when compared with Cosopt (dorzolamide 2%/timolol 0.5% ophthalmic solution; Merck).
Philippe Denis, MD, PhD, professor and head, Department of Ophthalmology, Edouard Herriot Hospital, Lyon, France, and colleagues conducted the randomized, 12-month, multicentre study comparing the safety and efficacy of each drug combination. Both Azarga and Cosopt were found to have similar IOP-lowering effects, achieving IOP values of 16.7–18.8 mmHg and 16.9–19.4 mmHg, respectively. The adverse event profile of Azarga (transient blurred vision) was, in the opinion of the researchers, more acceptable to patients than that of Cosopt (localized stinging/burning sensation).
According to the CHMP report, the most common side effects of Azarga - which is indicated for IOP reduction in adults with open-angle glaucoma or ocular hypertension in whom monotherapy has proved unsuccessful - are blurred vision, eye irritation, eye pain, and foreign body sensation.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
